Nuvation Bio Inc. (NYSE:NUVB) reported first‑quarter 2026 financial results that marked a dramatic turnaround from the prior year. Total revenue rose to $83.2 million, driven by $18.5 million in U.S. product revenue from its first‑line drug IBTROZI and $64.7 million in collaboration and license revenue. Net product revenue increased 18% from the prior quarter and more than 2,600% from $3.1 million in Q1 2025, reflecting the rapid uptake of IBTROZI and the impact of new partnership payments. Cash, cash equivalents, and marketable securities stood at $533.7 million as of March 31, 2026, giving the company a strong runway for continued investment.
The company’s earnings per share were $0.01, a significant improvement from the $‑0.16 per share reported for the same period a year earlier. While the $0.01 EPS was in line with or slightly below analyst expectations of $0.01 to $0.06, it marked a transition from a net loss to a modest profit, underscoring the financial benefits of the IBTROZI launch and the large upfront payment from its collaboration partner.
IBTROZI’s commercial launch continues to gain momentum. The company treated approximately 200 new patients in the quarter, the third consecutive quarter of about 200 starts, and for the first time since launch, more than half of those patients were TKI‑naïve. "We successfully treated approximately 200 new patients with IBTROZI in the first quarter, which makes three consecutive quarters of about 200 new patient starts, bringing our total to over 600 since launch. We see a growing trend of more new patients coming from the first‑line setting and, in turn, a lower percentage of patients coming from the third‑line setting or later," said CEO David Hung.
Collaboration and license revenue accounted for $64.7 million, largely driven by an upfront payment of nearly $60 million from Eisai under a partnership announced in January. "In addition to product revenue, we recognized $64.7 million in collaboration and license revenue in the quarter, including an upfront payment of nearly $60 million from Eisai pursuant to our partnership," CFO Philippe Sauvage said. "We also received approximately $1.7 million in royalty payments from our partnerships in Japan and China, both of which are exceeding initial expectations on a new patient starts and net revenue basis."
The company also secured exclusive global development and commercialization rights to safusidenib from Daiichi Sankyo, positioning it for future growth in the IDH1‑mutant glioma market. "We are also thrilled to have secured exclusive global development and commercialization rights to safusidenib from Daiichi Sankyo, positioning it for future growth in the IDH1‑mutant glioma market," Hung added. "We believe safusidenib has immense potential to address significant patient needs in IDH1‑mutant glioma, and our current development plan focuses on patient groups with limited or no FDA‑approved targeted treatment options."
Investors reacted with mixed sentiment, noting the strong revenue performance and the company’s cash position while also observing that EPS was only marginally better than expectations. The company did not disclose guidance for the next quarter, leaving analysts to assess the trajectory based on the current results and the momentum in IBTROZI adoption.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.